90%
of oncology drugs fail in trial
TheSemiconductor LayerFor Pharma
Building the frontier of pharmaceutical risk infrastructure. Human cardiac organoids and high-resolution genomics, surfacing drug-induced cardiac injury before it reaches a patient.
The Problem
Heart failure is a leading damaging effect and one of the most elusive to catch before the damage is done. Today's preclinical tools surface that risk years and hundreds of millions too late.
≤50%
of truly cardiotoxic drugs missed by today's standard tools
$300M
lost per failed drug
Our Solution
Our platform is the first of its kind to take this approach.
Human organoids
Biomanufactured cardiac tissue, QC'd batch to batch
Drug exposure
Your compound, run against living tissue
Risk genomics
High-resolution readout paired with pharmacodynamic risk
The product
Actionable go/no-go reports.
Every angle of risk captured against your compound, synthesized into a definitive answer on where to move the candidate next.
Who We Serve
- AI-enabled drug discovery teams
- Safety and toxicology R&D teams
We stand as the bridge between bench, clinic, and bedside — grounding high-conviction decisions with insight that otherwise blindsides you too late to act on.
Our Mission
Human-genome-backed resolution, so you see it before it becomes hindsight.
Cardiotoxicity remains one of the leading causes of late-stage drug failure, resulting in significant development delays, patient risk, and millions of dollars in lost R&D investment.
The field is moving fast, and it knows the urgency. What it lacks are tools that can keep pace. We give it that resolution — clearing the low-lying cardiac risk that holds innovation back, so therapies can move faster and with more confidence.
Contact
Cardiac risk, answered before the clinic.
If you are evaluating a compound with cardiac exposure — or building the models that will — we should talk.